CancerDrs

Pancreatic Cancer clinical trials in California

116 actively recruiting pancreatic cancer trials at 85 sites across California.

Data from ClinicalTrials.gov · last refreshed

Payments from drug makers to the doctors running these trials

For 3 of the trials on this page, the pharmaceutical company funding the trial also disclosed payments to the physicians leading it — public data from the federal CMS Open Payments database. Paying clinical-trial investigators for site work is expected and necessary for industry-funded trials; the scale and source are simply useful context when you're deciding whether to enroll.

Phase 3 Recruiting Academic/Other

Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer

This phase III trial compares the effect of dose-escalated radiation therapy to usual care in patients with locally advanced unresectable pancreatic ductal adenocarcinoma who have received an initial 4-8 months of chemotherapy. Usual care …

Sponsor: NRG Oncology
NCT ID: NCT06958328
Sites in California:
  • Mission Hope Medical Oncology - Arroyo Grande — Arroyo Grande, California
  • AIS Cancer Center at San Joaquin Community Hospital — Bakersfield, California
  • Alta Bates Summit Medical Center-Herrick Campus — Berkeley, California
  • Mills-Peninsula Medical Center — Burlingame, California
  • Sutter Cancer Centers Radiation Oncology Services-Cameron Park — Cameron Park, California
View on ClinicalTrials.gov →
Phase 3 Recruiting Network

Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations

This phase III trial compares the effect of adding panitumumab to standard chemotherapy (with nanoliposomal Irinotecan, leucovorin, and 5-fluorouracil \[5-FU\] or irinotecan, leucovorin, and 5-FU or nab-paclitaxel and gemcitabine) versus s…

Sponsor: SWOG Cancer Research Network
NCT ID: NCT06998940
Sites in California:
  • Mission Hope Medical Oncology - Arroyo Grande — Arroyo Grande, California
  • Sutter Auburn Faith Hospital — Auburn, California
  • Sutter Cancer Centers Radiation Oncology Services-Auburn — Auburn, California
  • Alta Bates Summit Medical Center-Herrick Campus — Berkeley, California
  • Providence Saint Joseph Medical Center/Disney Family Cancer Center — Burbank, California
View on ClinicalTrials.gov →
Phase 3 Recruiting Network

Lanreotide Versus Placebo Before Surgery to Prevent a Surgical Complication Called a Pancreatic Fistula

This phase III trial compares the effect of using lanreotide before surgery to surgery alone in preventing pancreatic fistulas in patients with pancreatic cancer or a pancreatic lesion that could become cancerous. Lanreotide, a type of som…

Sponsor: SWOG Cancer Research Network
NCT ID: NCT06807437
Sites in California:
  • City of Hope Comprehensive Cancer Center — Duarte, California
  • UC San Diego Moores Cancer Center — La Jolla, California
  • Veterans Affairs Loma Linda Healthcare System — Loma Linda, California
  • USC / Norris Comprehensive Cancer Center — Los Angeles, California
  • UC San Diego Medical Center - Hillcrest — San Diego, California
View on ClinicalTrials.gov →
Phase 2, Phase 3 Recruiting Industry

A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue

Study to investigate the efficacy, safety and tolerability of systemic chemotherapy plus ponsegromab versus systemic chemotherapy plus placebo for the first-line treatment in adult participants with cachexia and metastatic pancreatic ducta…

Sponsor: Pfizer
NCT ID: NCT06989437
Sites in California:
  • UC San Diego Medical Center - Encinitas — Encinitas, California
  • Chao Family Comprehensive Cancer Center and Ambulatory Care — Irvine, California
  • UCI Health - Irvine — Irvine, California
  • UC San Diego Koman Family Outpatient Pavilion — La Jolla, California
  • UC San Diego Medical Center - La Jolla (Jacobs Medical Center / Thornton Pavilion) — La Jolla, California
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma

The purpose of this study is to evaluate the efficacy and safety of standard chemotherapy with or without INCB161734 in participants with metastatic pancreatic ductal adenocarcinoma (PDAC).

Sponsor: Incyte Corporation
NCT ID: NCT07522073
Sites in California:
  • Investigative Site US051 — Duarte, California
  • Investigative Site US085 — Fullerton, California
  • Investigative Site US054 — La Jolla, California
  • Investigative Site US086 — Long Beach, California
  • Investigative Site US027 — Los Angeles, California
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer

Pancreatic cancer is difficult to diagnose early. By the time people have been diagnosed, the cancer has usually spread to other parts of the body (metastatic). The standard treatment is chemotherapy, but other treatments are needed to imp…

Sponsor: Astellas Pharma Global Development, Inc.
NCT ID: NCT07409272
Sites in California:
  • Crosson Cancer Institute at Providence St. Jude Medical Center in Fullerton — Fullerton, California
  • UCI Health - Irvine — Irvine, California
  • Cedars-Sinai - Cedars-Sinai Medical Center — Los Angeles, California
  • Hoag Mem Hosp Presbyterian — Newport Beach, California
  • UC Irvine Health-Chao Family Comprehensive Cancer Center — Orange, California
View on ClinicalTrials.gov →
Phase 2, Phase 3 Recruiting Industry

Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors

The primary purpose of this study is to assess the effectiveness of zanzalintinib compared to everolimus in participants with previously treated, unresectable, locally advanced or metastatic neuroendocrine tumors.

Sponsor: Exelixis
NCT ID: NCT06943755
Sites in California:
  • Cedars-Sinai Medical Center — Beverly Hills, California
  • Norris Comprehensive Cancer Center — Los Angeles, California
  • Stanford Cancer Center — Palo Alto, California
  • UCLA Health - Santa Monica Cancer Care — Santa Monica, California
  • Kaiser Permanente Medical Center — Vallejo, California
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma

The purpose of this study is to evaluate the safety and efficacy of an investigational RAS(ON) inhibitor administered as monotherapy or in combination with chemotherapy, compared with standard of care (SOC) chemotherapy alone.

Sponsor: Revolution Medicines, Inc.
NCT ID: NCT07491445
Sites in California:
  • University of California Los Angeles Health - Hematology/Oncology — Los Angeles, California
  • University of California San Francisco — San Francisco, California
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Carcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine Regimen

A Phase 3, randomized, double-blinded, placebo-controlled study to evaluate the efficacy and safety of paltusotine treatment vs placebo as well as the long-term safety of paltusotine in adults with carcinoid syndrome due to well-differenti…

Sponsor: Crinetics Pharmaceuticals Inc.
NCT ID: NCT07087054
Sites in California:
  • Hoag Memorial Hospital Presbyterian — Newport Beach, California
View on ClinicalTrials.gov →
Phase 2, Phase 3 Recruiting Industry

Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Pancreatic Cancer

The study is a randomized, double-blind, placebo-controlled, multicenter study of standard treatment with nab-paclitaxel and gemcitabine with or without SBP-101 in subjects previously untreated for metastatic pancreatic ductal adenocarcino…

Sponsor: Panbela Therapeutics, Inc.
NCT ID: NCT05254171
Sites in California:
  • Providence Medical Foundation — Fullerton, California
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

The Effect of Kinisoquin™ on Thromboembolic Events in Patients With Metastatic or Locally Advanced Pancreatic Cancer

The aim of this Phase 3 study is to evaluate the efficacy of Kinisoquin™ as compared to the placebo in prevention of thromboembolic events in patients with metastatic or locally advanced pancreatic cancer.

Sponsor: Quercis Pharma AG
NCT ID: NCT06861088
Sites in California:
  • Ventura Clinical Trials — Ventura, California
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Glufosfamide Versus 5-FU in Second Line Metastatic Pancreatic Cancer

The study is designed to assess whether glufosfamide provides additional survival benefit as compared to bolus 5-FU in patients with metastatic pancreatic cancer who have already progressed or failed therapy on a gemcitabine based first li…

Sponsor: Eleison Pharmaceuticals LLC.
NCT ID: NCT01954992
Sites in California:
  • Innovative Clinical Research Institute — Whittier, California
View on ClinicalTrials.gov →
Phase 2 Recruiting NIH

APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation

This phase II trial investigates how well the addition of olaparib following completion of surgery and chemotherapy works in treating patients with pancreatic cancer that has been surgically removed (resected) and has a pathogenic mutation…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT04858334
Sites in California:
  • Mission Hope Medical Oncology - Arroyo Grande — Arroyo Grande, California
  • PCR Oncology — Arroyo Grande, California
  • Alta Bates Summit Medical Center-Herrick Campus — Berkeley, California
  • Providence Saint Joseph Medical Center/Disney Family Cancer Center — Burbank, California
  • Palo Alto Medical Foundation-Fremont — Fremont, California
View on ClinicalTrials.gov →
Phase 2 Recruiting Network

Testing the Use of Chemotherapy After Surgery for High-Risk Pancreatic Neuroendocrine Tumors

This phase II trial studies the effect of capecitabine and temozolomide after surgery in treating patients with high-risk well-differentiated pancreatic neuroendocrine tumors. Chemotherapy drugs, such as capecitabine and temozolomide, work…

Sponsor: SWOG Cancer Research Network
NCT ID: NCT05040360
Sites in California:
  • Mission Hope Medical Oncology - Arroyo Grande — Arroyo Grande, California
  • PCR Oncology — Arroyo Grande, California
  • Tower Cancer Research Foundation — Beverly Hills, California
  • Keck Medicine of USC Buena Park — Buena Park, California
  • Providence Saint Joseph Medical Center/Disney Family Cancer Center — Burbank, California
View on ClinicalTrials.gov →
Phase 2 Recruiting Academic/Other

A Phase II Nationwide, Fully Decentralized, Telemedicine Study of Pemigatinib in Adult Patients With Advanced or Metastatic Pancreatic Cancer With FGFR Genetic Alterations

This phase II study evaluates how well pemigatinib works for the treatment of adult patients with pancreatic cancer that has spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced) or has s…

Sponsor: Sameek Roychowdhury
NCT ID: NCT06906562
Sites in California:
  • Ohio State University Telemedicine — Fresno, California
  • Ohio State University-Telemedicine — Los Angeles, California
  • Ohio State University-Telemedicine — San Diego, California
  • Ohio State University-Telemedicine — San Francisco, California
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting NIH

Testing the Addition of a New Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiotherapy in Patients With Locally Advanced Pancreatic Cancer

This phase I/II trial studies the safety, side effects and best dose of M3814 and to see how well it works when given together with radiation therapy in treating patients with pancreatic cancer that has spread to nearby tissue or lymph nod…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT04172532
Sites in California:
  • City of Hope Comprehensive Cancer Center — Duarte, California
  • UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care — Irvine, California
  • City of Hope at Irvine Lennar — Irvine, California
  • UC Irvine Health/Chao Family Comprehensive Cancer Center — Orange, California
  • University of California Davis Comprehensive Cancer Center — Sacramento, California
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors

This clinical trial is evaluating a drug called ART0380 in participants with advanced or metastatic solid tumors. The main goals of this study are to: * Find the recommended dose of ART0380 that can be given safely to participants alone an…

Sponsor: Artios Pharma Ltd
NCT ID: NCT04657068
Sites in California:
  • USC Norris Comprehensive Cancer Center — Los Angeles, California
  • Sansum Clinic — Santa Barbara, California
  • Providence Medical Foundation — Santa Rosa, California
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors

The purpose of this platform study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of novel RAS(ON) inhibitors combined with Standard(s) of Care (SOC) or with novel agents. The current sub…

Sponsor: Revolution Medicines, Inc.
NCT ID: NCT06445062
Sites in California:
  • UC San Diego Moores Cancer Center — La Jolla, California
  • Cedars-Sinai Cancer at Cedars-Sinai Medical Center — Los Angeles, California
  • UCLA Hematology/Oncology- Santa Monica — Los Angeles, California
View on ClinicalTrials.gov →
Phase 2 Recruiting Industry

Safely Optimizing Body Weight With Mifomelatide (TCMCB07) in Patients With Newly Diagnosed Colorectal Cancer (CRC) or Pancreatic Ductal Adenocarcinoma (PDAC) Undergoing Chemotherapy

This is a randomized, double-blind, placebo-controlled basket trial evaluating mifomelatide (TCMCB07) administered daily by subcutaneous (SC) injection in up to 120 patients. Patients will be enrolled into two cohorts 1) patients with newl…

Sponsor: Endevica Bio
NCT ID: NCT06937177
Sites in California:
  • Cedars-Sinai Medical Center — Los Angeles, California
  • UCLA Medical Center — Santa Monica, California
View on ClinicalTrials.gov →
Phase 2 Recruiting Industry

A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Pancreatic Cancer

This study will assess the safety and efficacy of VS-7375 alone and in combination with cetuximab in patients with metastatic KRAS G12D - mutated Pancreatic Cancer

Sponsor: Verastem, Inc.
NCT ID: NCT07644559
Sites in California:
  • START- Los Angeles — Los Angeles, California
  • Cedars-Sinai Medical Center — Los Angeles, California
  • Valkyrie Clinical Trials — Los Angeles, California
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors

This study is to evaluate the safety, tolerability, and PK profiles of Elironrasib and Daraxonrasib as monotherapies and combination therapy in patients with KRAS G12C-mutated solid tumors.

Sponsor: Revolution Medicines, Inc.
NCT ID: NCT06128551
Sites in California:
  • City of Hope — Duarte, California
  • UC IRVINE Health — Orange, California
  • UC Davis Comprehensive Cancer Center — Sacramento, California
  • Stanford Cancer Institute — Stanford, California
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Network

Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors

This phase I/II trial evaluates the highest safe dose, side effects, and possible benefits of tegavivint in treating patients with solid tumors that has come back (recurrent) or does not respond to treatment (refractory). Tegavivint interf…

Sponsor: Children's Oncology Group
NCT ID: NCT04851119
Sites in California:
  • Children's Hospital Los Angeles — Los Angeles, California
  • Children's Hospital of Orange County — Orange, California
  • Lucile Packard Children's Hospital Stanford University — Palo Alto, California
  • UCSF Medical Center-Mission Bay — San Francisco, California
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors

This study will help find the most suitable dose of ASP546C in people with gastric cancer, gastroesophageal junction (GEJ) cancer, pancreatic cancer, and other specific solid tumors. GEJ is where the food pipe (esophagus) joins the stomach…

Sponsor: Astellas Pharma Global Development, Inc.
NCT ID: NCT07488676
Sites in California:
  • START Los Angeles — Los Angeles, California
View on ClinicalTrials.gov →

Showing 25 of 116 trials with sites in California. See all pancreatic cancer trials →

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-10-01